Altered expression profile of micrornas in gastric stromal tumor

Abstract

MicroRNAs (miRNAs) play important roles in carcinogenesis, but the global miRNA expression profile in gastric stromal tumor tissues remains unclear. This study was to examine the miRNA expression profile in gastric stromal tumor tissues and explore the function of dysregulated miRNAs by performing gene ontology (GO) and pathway enrichment analysis. Total RNA was extracted and purified from 3 pairs of frozen gastric stromal tumor tissues and the adjacent non-tumor tissues by using mirVana™ miRNA isolation kit. The miRNA expression was analyzed with Affymetrix microarrays (version 4.0) containing 2578 human mature microRNA probes. The dysregulated microRNAs were validated by quantitative RT-PCR in 30 pairs of gastric stromal tumor tissues. The target gene of the dysregulated microRNAs was predicted by miRanda, TargetScan and PicTar. GO and pathway enrichment analysis was conducted to examine the potential function of miR-3178 and miR-193a-5p. The results showed that there were 12 differently expressed microRNAs in gastric stromal tumor tissues, among which 10 miRNAs were down-regulated, and 2 were up-regulated (P<0.05). The validation results by RT-PCR were in accordance with those by microRNA microarry. GO analysis found that the target genes of miR-3178 were involved in 5 GO terms and those of miR-193a-5p in 7 GO terms in level 2. Pathway enrichment analysis suggested that miR-3178 and miR-193a-5p were related to 57 and 122 signaling pathways, respectively. It was concluded that gastric stromal tumor displays a unique miRNA signature. This specific expression may become a new diagnostic and prognostic biomarker for gastric stromal tumor. miR-3178 and miR-193a-5p function as suppressive microRNAs, and they may also become diagnosis and treatment targets for gastric stromal tumor.

Keywords

microRNA / gastric stromal tumor / signal pathway / gene

References

[1] BlayJY, BonvalotS, CasaliP, et al. . Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol, 2005, 16(4): 566-578

[2] NilssonB, BummingP, Meis-KindblomJM, et al. . Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer, 2005, 103(4): 821-829 PMID: 15648083

[3] MiettinenM, LasotaJ. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol, 2006, 23(2): 70-83 PMID: 17193820

[4] HirotaS, IsozakiK, MoriyamaY, et al. . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580 PMID: 9438854

[5] KindblomLG, RemottiHE, AldenborgF, et al. . Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol, 1998, 152(5): 1259-1269 PMCID: 1858579 PMID: 9588894

[6] SekineM, ImaokaH, MizunoN, et al. . Clinical course of gastrointestinal stromal tumor diagnosed by endoscopic ultrasound-guided fine-needle aspiration. Dig Endosc, 2015, 27(1): 44-52 PMID: 25059428

[7] MoehlerM, VoigtJ, KastorM, et al. . Endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) as primary diagnostic tool for unclear lesions in the upper gastrointestinal tract. Dtsch Med Wochenschr, 2011, 136(7): 303-308 PMID: 21302203

[8] BartelDP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116(2): 281-297 PMID: 14744438

[9] HwangHW, MendellJT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer, 2006, 94(6): 776-780 PMCID: 2361377 PMID: 16495913

[10] LewisBP, BurgeCB, BartelDP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1): 15-20 PMID: 15652477

[11] IorioMV, FerracinM, LiuCG, et al. . MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 2005, 65(16): 7065-7070 PMID: 16103053

[12] LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001, 25(4): 402-408 PMID: 11846609

[13] KandaT. Criminal or bystander: imatinib and second primary malignancy in GIST patients. Chin J Cancer Res, 2013, 25(5): 490-492 PMCID: 3828432 PMID: 24255570

[14] LiZY, TangL, LiSX, et al. . Imatinib mesylate in clinically suspected gastric stromal tumors. Chin J Cancer Res, 2013, 25(5): 600-602 PMCID: 3828431 PMID: 24255585

[15] ZhaoX, YueC. Gastrointestinal stromal tumor. J Gastrointest Oncol, 2012, 3(3): 189-208 PMCID: 3418531 PMID: 22943011

[16] LieglB, HornickJL, AntonescuCR, et al. . Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression. Am J Surg Pathol, 2009, 33(2): 218-226 PMID: 18830121

[17] SubramanianS, LuiWO, LeeCH, et al. . MicroRNA expression signature of human sarcomas. Oncogene, 2008, 27(14): 2015-2026 PMID: 17922033

[18] GitsCM, van KuijkPF, JonkersMB, et al. . MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumors. Br J Cancer, 2013, 109(6): 1625-1635 PMCID: 3776993 PMID: 23969726

[19] HallerF v, HeydebreckA, ZhangJD, et al. . Localization-and mutation-dependent microRNA (miRNA) expression signatures in gastrointestinal stromal tumours (GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J Pathol, 2010, 220(1): 71-86 PMID: 19768731

[20] YamamotoH, OdaY. Gastrointestinal stromal tumor: Recent advances in pathology and genetics. Pathol Int, 2015, 65(1): 9-18 PMID: 25414046

[21] BlandamuraS, AlessandriniL, BertorelleR, et al. . Multiple sporadic gastrointestinal stromal tumors concomitant with ampullary adenocarcinoma: a case report with KIT and PDGFRA mutational analysis and miR-221/222 expression profile. Pathol Res Pract, 2014, 210(6): 392-396 PMID: 24674454

[22] FanR, ZhongJ, ZhengS, et al. . MicroRNA-218 inhibits gastrointestinal stromal tumor cell and invasion by targeting KIT. Tumour Biol, 2014, 35(5): 4209-4217 PMID: 24375253

[23] YamamotoH, KohashiK, FujitaA, et al. . Fascin-1 overexpression and miR-133b downregulation in the progression of gastrointestinal stromal tumor. Mod Pathol, 2013, 26(4): 563-571 PMID: 23196799

[24] Chun-ZhiZ, LeiH, An-LingZ, et al. . MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. Bmc Cancer, 2010, 10: 367 PMCID: 2914702 PMID: 20618998

[25] NiinumaT, SuzukiH, NojimaM, et al. . Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res, 2012, 72(5): 1126-1136 PMID: 22258453

[26] ChoiHJ, LeeH, KimH, et al. . MicroRNA expression profile of gastrointestinal stromal tumors is distinguished by 14q loss and anatomic site. Int J Cancer, 2010, 126(7): 1640-1650 PMID: 19795448

[27] AkcakayaP, CaramutaS, AhlenJ, et al. . microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome. Br J Cancer, 2014, 111(11): 2091-2102 PMCID: 4260040 PMID: 25349971

[28] GaoX, ShenK, WangC, et al. . MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors. Acta Biochim Biophys Sin (Shanghai), 2014, 46(1): 72-75

[29] LiuS, CuiJ, LiaoG, et al. . MiR-137 regulates epithelialmesenchymal transition in gastrointestinal stromal tumor. Tumour Biol, 2014, 35(9): 9131-9138 PMID: 25027394

[30] HechtmanJ D, MatteoR, NafaK, et al. . Additional primary malignancies in patients with gastrointestinal stromal tumor (GIST): A clinicopathologic study of 260 patients with molecular analysis and review of the literature. Ann Surg Oncol, 2015, 22(8): 2633-2639 PMID: 25564173

[31] KouY, ZhaoY, BaoC, et al. . Comparison of gene expression profile between tumor tissue and adjacent non-tumor tissue in patients with gastric gastrointestinal stromal tumor (GIST). Cell Biochem Biophys, 2015